trial

Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole

NCTId NCT00567099
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Unknown
Enrollment 20 (estimated)
Sponsored by New Mexico VA Healthcare System
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
20 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2003-08
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Aripiprzole

Sponsors

New Mexico VA Healthcare SystemLead Sponsor
Bristol-MyersCollaborator

Investigators

1
Jose M Canive, MDPrincipal Investigator

Sites

1 total
Albuquerque, United States

Facts & assertions

3 sourced
Enrollment
20
Phase
NA
Status
UNKNOWN
relationships
The graph out of here
drug
Aripiprzole
drug
lead_sponsor
New Mexico VA Healthcare System
company
collaborator
Bristol-Myers
company
indication
Schizophrenia
indication
Schizophrenia
indication
Sensory Gating
indication
investigator
Jose M Canive, MD
person